Form 4: Cytokinetics Executive Andrew Callos Sells Shares to Cover Restricted Stock Unit Vesting

EVP and Chief Commercial Officer of Cytokinetics, Andrew Callos, sold 2,775 shares of common stock on March 17, 2025, to cover the vesting of restricted stock units.

Summary

• On March 17, 2025, Andrew Callos, the EVP and Chief Commercial Officer of Cytokinetics Inc. (CYTK), sold 2,775 shares of common stock.
• The sale was executed at a price of $44.38 per share.
• This transaction was a 'sell to cover' transaction related to the vesting of restricted stock units.
• Following the transaction, Callos directly owns 34,888 shares of Cytokinetics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive stock sale to cover vesting, which is a neutral event.

Industry Context

Executive stock sales are a common occurrence, particularly when related to the vesting of stock options or restricted stock units. These transactions are often disclosed via SEC Form 4 filings and provide transparency into executive compensation and ownership.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the impact is likely minimal given the relatively small number of shares sold.

Key Dates